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Supplementary Materials 
 
1. Development and evaluation of a secretin radioimmunoassay  
We obtained the following three secretin antisera: 1) ab103619 (Abcam, United Kingdom), 2) LS-
C402778 (LSBio, Seattle, USA), 3) A C-terminally directed secretin antibody (codename 5595-3) 
kindly provided by Professor Jan Fahrenkrug (Department of Clinical Biochemistry, Bispebjerg 
Hospital, Copenhagen, Denmark). The binding region of antibody 1 and 2 was not known.  
Cross-reactivity in the secretin assay was assessed for the following peptides: Glucagon 1-29 (Cat. 
No.: H-6790, Bachem), oxyntomodulin (Cat. No.: H-6058, Bachem), and glicentin (GenScript, 
Piscataway, USA, custom made service no. SC1208) as well as CCK-8 (Cat. No.:4033010, Bachem), 
recombinant human insulin (Cat. No.: ab86658, Abcam), neurotensin (Cat. No.: N6383, Sigma) and 
human PYY 3-36 (Cat. No.:4018880, Bachem). 
Commercially available secretin ELISAs (LS-F27215 (LSBio) and CEB075Hu (Cloud Clone, Texas, 
USA) were included in our assay evaluation for comparison with our in-house developed assay. 
Assays were evaluated according to the CLSI (Clinical and Laboratory Standards Institute) guidelines 
for Immunoassay (I/LA23-A, I/LA21-A2, and EP24-A) as previously described (2). 
Recovery in percent was calculated as the measured concentration in the individual, spiked plasma 
sample minus the concentration in the corresponding non-spiked plasma sample divided by the 
theoretical spiked concentration of peptide and multiplied by 100.  
Specificity was analyzed from recovery experiments. Known amounts of each peptide (5–
300 pmol/L) were added to separate aliquots of healthy human plasma (a reserve plasma pool from a 
previous study (1) was used). One aliquot was measured in duplicate, using two separate assay runs 
or kits for each of the two commercial ELISAs. 
Sensitivity was estimated by determining the lowest concentrations of added peptide that could be 
measured as being significantly different from zero (by paired analysis of three duplicate 
determinations) using a plasma pool spiked with 0, 1, 2, 5 pmol/L of human secretin. Precision was 
determined from multiple measurements of identical samples. 
For all kits, the manufacturers' instructions were followed closely, including recommendations for 
sample preparation by extraction (purification columns and buffers). 
 
  
2. Peptide extraction in rat tissue biopsies  
The biopsies were cleaned in PBS and snap frozen on dry ice before storage at -80°C. Peptides were 
extracted using 1% trifluoroacetic acid (cat no. TS-28904, Thermo Fisher Scientific, USA) and 
homogenized with a bead mill (TissueLyzer, Qiagen Instruments AG, Switzerland) and a 5 mm steel 
bead. Peptides were purified using tc18 cartridges (cat no. 036810 Waters, USA). Before analysis of 
secretin and GLP-1 peptide content, samples were reconstituted in 1 ml assay buffer (80 mmol/L 
phosphate buffer, 10 mmol/L EDTA, 0.6 mM Thimerosal (cat no. T-5125, Sigma Aldrich, Denmark), 
0.1% Human Serum Albumin (cat no. 12666, Merck KgaA, Germany), pH 7.5). Peptide content was 
normalized to tissue weight (pmol/g).  
 
3. Immunohistochemistry  
Tissue were paraffin-embedded on a HistoStar embedding workstation (Thermo Fisher Scientific, 
Massachusetts, USA), cut on a HM355S automatic microtome (Thermo Fisher Scientific, 
Massachusetts, USA) (4 μm) and mounted on cover slides. Next, the slides were heated at 60°C for 
60 minutes to remove the paraffin and placed in a TissueClear bath for 10 min followed by several 
baths at decreasing ethanol concentrations, from 99-70%, to hydrate the samples. Heat-induced 
antigen retrieval was done by microwaving samples for 15 min, in a T-EG buffer (pH 6, 0.5mmol/L 
Trisma base, Cat. no. T6066, Sigma-Aldrich, Missouri, USA, 1mM EGTA, Cat. no. E4378, Sigma-
Aldrich, Missouri, USA) and leaving them in the warm buffer for 20 min. Samples were washed with 
PBS, and blocked in 2% (w/v) BSA for 10 min. Then incubated with the primary antibody (1:20000, 
Polyclonal Rabbit Anti-Secretin (5585-3), a generous gift from J. Fahrenkrug at Bispebjerg Hospital, 
Copenhagen, Denmark) for 1 hour, washed three times 1 minute in wash buffer (EnV FLEX wash 
buffer 20x, Cat. no K800721-2, Agilent, Glostrup, Denmark) before incubating samples with 
secondary antibody (1:200, Polyclonal, biotinylated Anti-rabbit, Cat. no. BA-1000, Vectorlabs, 
California). Samples were washed three times in wash buffer, incubated in 3% (v/v) H2O2 for 8 min 
at 37°C, followed by three washes, and incubation with the Vectastain Elite ABC complex (mixed 30 
min prior to use according to supplier instructions, Cat. no. PK-6100 Vectorlabs, California, USA). 
Another three washes were carried out before developing the sections by incubation with DAB+ 
(mixed according to supplier instructions, Cat no. SK4105, Vectorlabs, California, USA), for 15 min. 
Sections were washed in Milli Q water for 5 min and bathed in hematoxylin for ~30 seconds. The 
slides were rinsed in a Milli Q water bath to remove any excess hematoxylin before mounting 
coverslips with PERTEX mounting medium (HistoLab, Västra Frölunda, Sweden). 
4. Isolated perfused rat small intestine and pancreas 
Non-fasted rats were anaesthetized with a subcutaneous injection of Hypnorm/Midazolam. The 
proximal and the distal small intestines (45±5 cm) were isolated by ligating the blood supply and 
removing the colon and either the proximal or the distal half of the small intestine. A catheter was 
inserted into the superior mesenteric artery and the intestine was perfused at a constant flow rate of 
7.5 mL/min with a heated (37°C), oxygenated (95% O2, 5% CO2) perfusion buffer (pH 7.4). To 
remove intestinal contents, a plastic tube was placed in the lumen of the intestine and the intestine 
was gently flushed with pre-warmed saline (0.9%). Throughout the experimental protocol, a constant 
luminal flow of heated saline was applied via a syringe pump (0.25 mL/min). The venous effluent 
was collected from a catheter inserted into vena portae.  
Pancreas was isolated by removing the large and small intestine, the spleen and the stomach after 
ligation of their specific vessels. The renal arteries were ligated and the abdominal aorta was ligated 
below the diaphragm. A catheter was inserted into the abdominal aorta proximal to the renal arteries 
and the pancreas was perfused at a constant flow rate of 5 mL/min. The venous effluent was collected 
from a catheter in vena portae. As soon as proper flow was apparent, the rats were euthanized by 
perforation of the diaphragm. For stabilization, the organs were perfused for 25 minutes before 
initiation of the experimental protocol.  
Perfusion buffer was a Krebs-Ringer bicarbonate buffer supplemented with 5% (w/v) dextran T-70 
(Pharmacosmos, Denmark), 0.1% (w/v) bovine serum albumin (cat. no. 1.12018.0500, Merck, 
Denmark), 5 mmol/L of each pyruvate, fumarate and glutamate (Sigma Aldrich, Denmark). The 
perfusion buffer contained 3.5 mmol/L glucose in the perfused intestine and 10 mmol/L glucose in 
the perfused pancreas. 
The venous effluent was collected for 1 min periods via the draining catheter using a fraction 
collector. The samples were immediately put on ice and stored at -20°C until analysis. 
 
5. In situ hybridization 
Pancreases were excised from non-fasted rats and transferred to fresh 4% paraformaldehyde (PFA), 
PBS for 24h at room temperature. Tissue was then transferred to 70% ethanol followed by infiltration 
(Shandon Excelsior, Thermo Fisher), and embedded in paraffin blocks. Sections of 4 μm were cut 
using a microtome (RM2125, Leica) and mounted on slides (superfrost Plus Slides, Thermo 
Scientific). The slides were baked at 60 °C for 1h and placed in xylene and ethanol for dewaxing. The 
in situ hybridization was performed using mRNA specific probes (Supplementary Table 3) following 
the manufacturers’ manual of a commercially available in situ hybridization kit, RNAscope 2.5 HD 
detection (Cat.no. 322360, Advanced Cell Diagnostics, Milan, Italy) in combination with 
immunofluorescence. After the in situ hybridization procedure, the slides were incubated with 
blocking buffer (2 % BSA, PBS for 10 minutes) followed by incubation with primary insulin, 
glucagon or somatostatin antibody in blocking buffer (Supplementary Table 2) over night at 4 °C. 
The day after the slides were washed and incubated with Alexafluor 488 conjugated secondary 
antibodies for 1 hour at room temperature (Supplementary Table 2). Coverslips were then mounted 
with ProLong Gold 32 Antifade Mountant with DAPI (P-3693 I, Thermofisher). The slides were 
analyzed using a Zeiss Widefield fluorescence microscope and AxioCam 506 mono camera or a Zeiss 
Axio Scan.Z1 Slide Scanner and AxioCam MRm camera. 
 
 
  
Supplementary Figures 
 
Supplementary Figure 1: Evaluation of an in-house secretin assay 
In-house developed assay calibrator curve showing 95% CI and corresponding details of the non-linear 
regression fit (a 4-parametric logistic regression model) below. 
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Best-fit values  
Top 2417 
Bottom 361,6 
LogIC50 1,279 
HillSlope -1,033 
IC50 19,01 
Span 2056 
95% CI (profile likelihood)  
Top 2271 to 2651 
Bottom 118,7 to 507,6 
LogIC50 1,172 to 1,387 
HillSlope -1,354 to -0,7423 
IC50 14,87 to 24,40 
 
Goodness of Fit  
Degrees of Freedom 50 
R squared 0,9645 
Sum of Squares 903621 
Sy.x 134,4 
Supplementary Figure 2: Bland-Altman plots of assay B versus assay A, and assay C versus assay A 
Assay A: In-house RIA, Assay B: LS-F27215 (LSBio) and Assay C: CEB075Hu (Cloud Clone, Texas, 
USA). Human secretin was spiked in human plasma at different final concentrations and a bland-Altman 
analysis was performed using GraphPad Prism. The differences (%) was visualized as shown below for 
the two comparisons to the in-house developed assay.  
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Supplementary Tables 
 
Supplementary Table 1: Anatomical Definitions  
 
 
 
 
 
 
 
 
 
Supplementary Table 2: Antibody Table 
 
 
Supplementary Table 3: Probe Table 
 
Nomenclature used 
in the manuscript 
Anatomical Location 
Esophagus 0.5 cm proximal to esophageal sphincter 
Ventricle 1 cm proximal to pyloric sphincter (antrum) 
Duodenum 1 cm distal to pyloric sphincter 
Proximal Jejunum 6 cm distal to pyloric sphincter 
Distal Ileum 1 cm proximal to ileocecal junction 
Colon Mid part of colon 
Target protein 
Manufacturer/ 
Provider and cat. no. 
Host 
IHC dilutions 
for in situ 
hybridization 
IHC dilutions 
for secretin 
localization 
Insulin In-house, 2006-4 
Guinea 
Pig 
1:3000 - 
Somatostatin In-house, 1759 Rabbit 1:3000 - 
Glucagon Abnova, MAB1500 Mouse 1:300 - 
Secretin 
A gift from 
Fahrenkrug,5585-3 
Rabbit - 1:20000 
CF488A anti-Guinea pig IgG Biotium, 20169 Donkey 1:200 - 
Alexa fluor 488 anti-rabbit 
IgG 
Abcam, ab150109 Donkey 1:200 - 
Alexa fluor 488 anti-rabbit 
IgG 
Abcam, ab150081 Goat 1:200 - 
Biotinylated anti-rabbit IgG 
Vector Laboratories, BA-
1000 
Goat - 1:200 
Target mRNA Target species 
Manufacturer/ 
Provider and cat. no. 
Accession 
no. 
Secretin receptor (Sctr) Rattus norvegicus ACD biotechne, 
580701 
NM_031115.1 
Peptidylprolyl isomerase B (Ppib) Rattus norvegicus ACD biotechne, 
313921 
NM_022536.2 
Dihydrodipicolinate reductase (DapB) Bacillus subtilis strain SMY ACD biotechne, 
310043 
EF_191515 
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